Pricing and Reimbursement

The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines

Health interventions can produce economic gains for patients and national economies. In practice, however, the health-wealth link is rarely considered.

OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.

Recently published is a new OHE research paper entitled ‘Model of Behaviour within Fuzzy Budget Constraints’. The paper presents a model to capture the behaviour of health sector decision makers.

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.

On Tuesday 6th October, James Anderson (GSK), Ri De Ridder (RIZIV-INAMI), and Sophia Tickell (Meteosan) will take part in an OHE seminar to discuss the Checklist for Collaborative, Mutually Acceptable Drug Pricing.

This article looks at how theory could be put into practice suggesting ways to implement a differential pricing system for branded medicines in the EU that can enhance overall welfare.

This post provides an overview of Dr Irene Papanicolas and Professor Alistair McGuire’s OHE Lunchtime Seminar on the effect of financial incentives on hip replacement in England.

This post is the second of a two part summary of OHE’s scheduled activity at ISPOR Philadelphia 2015.

Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the USA just published online.

Pages

Subscribe to RSS - Pricing and Reimbursement